The 5-HT1A receptor as a serotonergic target for neuroprotection in cerebral ischemia

Citation for published version (APA):

Document status and date:
Published: 13/07/2021

DOI:
10.1016/j.pnpbp.2020.110210

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 17 Sep. 2023
The 5-HT1A receptor as a serotonergic target for neuroprotection in cerebral ischemia

Rafael Pazinatto de Aguiar a, Adrian Newman-Tancredi b, Jos Prickaerts c, Rúbia Maria Weffort de Oliveira a,b*

a Department of Pharmacology and Therapeutics, State University of Maringá, Av. Colombo, 5790, CEP 87020-900, Maringá, Paraná, Brazil
b Neurolixis, Castres, France
c Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

ARTICLE INFO

Keywords:
Cerebral ischemia
Serotonin
5-HT1A receptor
Neuroprotection

ABSTRACT

Cerebral ischemia due to stroke or cardiac arrest greatly affects daily functioning and the quality of life of patients and has a high socioeconomic impact due to the surge in their prevalence. Advances in the identification of an effective pharmacotherapy to promote neuroprotection and recovery after a cerebral ischemic insult are, however, limited. The serotonin 1A (5-HT1A) receptor has been implicated in the regulation of several brain functions, including mood, emotions, memory, and neuroplasticity, all of which are deleteriously affected by cerebral ischemia.

This review focuses on the specific roles and mechanisms of 5-HT1A receptors in neuroprotection in experimental models of cerebral ischemia. We present experimental evidence that 5-HT1A receptor agonists can prevent neuronal damage and promote functional recovery induced by focal and transient global ischemia in rodents. However, indiscriminate activation of pre- and postsynaptic by non-biased 5-HT1A receptor agonists may be a limiting factor in the anti-ischemic clinical efficacy of these compounds since 5-HT1A receptors in different brain regions can mediate diverging or even contradictory responses. Current insights are presented into the ‘biased’ 5-HT1A post-synaptic heteroreceptor agonist NLX-101 (also known as F15599), a compound that preferentially and potently stimulates postsynaptic cortical pyramidal neurons without inhibiting firing of serotonergic neurons, as a potential strategy providing neuroprotection in cerebral ischemic conditions.

1. Introduction

Cerebral ischemia resulting from stroke or cardiac arrest and is one of the leading causes of death and disability worldwide, presenting a significant global burden to patients, their relatives, and entire economies (Flynn et al., 2008; Benjamin et al., 2018; Rajsic et al., 2019). Patients who survive an ischemic cerebral insult are particularly vulnerable to the development of motor and cognitive impairments, depression, and anxiety disorders (Moulaert et al., 2010; Geri et al., 2014). Despite intense preclinical efforts, however, only limited advances have been made to develop effective therapies to promote recovery from cerebral ischemia (Ginsberg, 2009; Dirnagl and Endres, 2014).

Serotonin 5-HT1A receptors have been implicated in the regulation of several brain functions such as motor function, body temperature, neuroendocrine activity, mood, emotion, and, memory. All these functions may be affected by cerebral ischemia. Besides, 5-HT1A receptors have been a target for neuroprotection in animal models of cerebral ischemia. However, indiscriminate activation of pre- and postsynaptic by 5-HT1A receptor agonists may produce no therapeutic benefits in patients. The lack of receptor discrimination may be a limiting factor in the therapeutic efficacy of the agonists because 5-HT1A receptors in different brain regions can mediate diverging or even contradictory responses. In this review, we present experimental evidence that 5-HT1A receptor agonists can prevent neuronal damage and promote functional recovery induced by focal or transient global ischemia in rodents. We also discuss the biased 5-HT1A agonist NLX-101 (also known as F15599), a compound that preferentially and potently stimulates postsynaptic cortical pyramidal neurons without inhibiting serotonin neuron firing (Newman-Tancredi et al., 2009; Llado-Pelfort et al., 2010).

* Corresponding author.
E-mail address: rmmwoliveira@uem.br (R.M.W. Oliveira).

https://doi.org/10.1016/j.pnpbp.2020.110210
Received 26 August 2020; Received in revised form 1 December 2020; Accepted 10 December 2020
Available online 14 December 2020
0278-5846/© 2020 Elsevier Inc. All rights reserved.
2. Serotonin and serotonin receptors

Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine which is widely distributed in the central nervous system. As a neurotransmitter, 5-HT is involved in almost every brain’s physiological function and plays essential roles in hormonal control, sleep, body temperature, appetite, mood, motor activity, and cognition (Feijo Fde et al., 2010; David and Gardier, 2016; Haleem, 2019).

Serotonergic neurons arise from the brainstem raphe nuclei, i.e., the dorsal raphe nucleus (DRN), median raphe nucleus (MRN), and caudal raphe nucleus (CRN) (Bang et al., 2012). The DRN and MRN project serotonergic fibers through the medial forebrain bundle (MFB) to frontal areas, while the CRN innervates cerebellar and spinal targets (Jacobs and Azmitia, 1992; Gaspar and Lillesaar, 2012; Maddaloni et al., 2017).

Most of the projections that reach the DRN come from the hypothalamus, medulla, cortex, and amygdala. The MRN receives projections from the amygdala, prefrontal cortex (PFC), and other cortical areas, and mainly from the hypothalamus and midbrain (Pollak Dorocic et al., 2014).

5-HT is synthesized in two steps from the essential amino acid L-tryptophan acquired from the diet. Tryptophan is hydroxylated at position 5 to 5-hydroxytryptophan by tryptophan hydroxylase (TPH) is the rate-limiting enzyme, and then decarboxylated by the amino acid L-amino-aromatic enzyme, to 5-HT (Walther et al., 2003). Two TPH isoforms have been identified: TPH1 which is expressed in non-neuronal cells such as enterochromaffin and mast cells (Fitzpatrick, 1999), and the TPH2 isoform which is expressed in the raphe nuclei and myenteric plexus (Walther et al., 2003). After synthesis, 5-HT storage occurs in vesicles present in presynaptic neurons. Once released in the synaptic cleft, 5-HT may act on pre- or postsynaptic serotonergic receptors. Subsequently, 5-HT is taken up through the serotonin transporter (SERT), and then decarboxylated by the amino acid L-amino-aromatic enzyme, to 5-HT (Pollak Dorocic et al., 2014).

Serotonergic receptors are proteins that are bound to membranes and grouped into families according to their associated system of second messengers, their amino acid sequence, or their functional homology. The functional responses to 5-HT are mediated by 7 different families of receptors, designated 5-HT1 to 5-HT7, which are further divided into 15 subtypes (Hoyer et al., 1994; Bockaert et al., 2010; Hannon and Hoyer, 2008; Table 1). Except for the 5-HT3 ionotropic receptor, all other 5-HT receptors are classical metabotropic G-protein coupled receptors (GPCR) which couple to canonical signaling pathways through Gα, Gβγ, and Gαq/11 and elicit the expected second messenger cascades (Nichols and Nichols, 2008). The Gαi-coupled serotonin receptors encompass the 5-HT1 and 5-HT3 types, leading to inhibition of adenyl cyclase (AC) and a consequent decrease of cyclic adenosine monophosphate (cAMP) levels (Lin et al., 2002). The Gαq11-coupled serotonin receptors include the 5-HT2 receptor subtypes, which are linked to activation of phospholipase C (PLC), producing inositol triphosphate (IP3) and diacylglycerol (DAG), ultimately leading to an increase in intracellular calcium (Ca2+)(Roth et al., 1998). 5-HT3, 5-HT6, and 5-HT7 coupled to the stimulatory G protein (Gαs) and stimulate AC and protein kinase A (PKA), leading to increased levels of cAMP (Polter and Lit, 2010) (Table 1). Metabotropic 5-HT receptor function may also elicit non-canonical signals that can be either mediated by a host of alternative G-proteins or be G-protein-independent. G-protein independent signaling may involve β-arrinthes which are associated with other signaling pathways such as the mitogen-activated protein kinases including extracellular signal-regulated kinase (ERK) (Schmid et al., 2008; McCorvy and Roth, 2015). These pathways can also be activated via G-protein mediated mechanisms. Arrestin has been associated with GPCR desensitization (Freedman and Lefkowitz, 1996) and internalization (Ferguson et al., 1996), indicating the clinical importance of this signaling pathway to tolerance development and therapeutic efficacy of drugs (Violin et al., 2014).

3. The 5-HT1A receptor

The 5-HT1 receptor family is divided into 6 subtypes: A, B, C, D, E, and F (Peroutka, 1988). Among all the subtypes, the 5-HT1A receptor is most studied and characterized because of its involvement in the pathophysiology and treatment of several psychiatric and neurological conditions such as anxiety, depression, Parkinson’s disease, and Alzheimer’s disease (Pazos et al., 1985; Celada et al., 2013; Garcia-Garcia et al., 2014; Albert and Vahid-Ansari, 2019). The induction of adult neurogenesis by antidepressants and remodeling of corticolimbic circuits has also been related to the stimulation of 5-HT1A receptors (Santarelli et al., 2003). Moreover, novel antidepressants and antipsychotics have begun to incorporate 5-HT1A agonist activity to enhance their therapeutic efficacy. Clozapine and the more recent antipsychotics aripiprazole, brexpiprazole, perospirone, and cariprazine, for example, have begun to incorporate 5-HT1A agonist activity to enhance their therapeutic efficacy. Clozapine and the more recent antipsychotics aripiprazole, brexpiprazole, perospirone, and cariprazine, for example, exhibit partial agonist properties at 5-HT1A receptors and may alleviate a deficiency in dopaminergic transmission in frontocortical regions of schizophrenic patients, thus improving negative and cognitive symptoms. Further, 5-HT1A receptor activation has been shown to reduce extrapyramidal symptoms induced by neuroleptics (for review see Newman-Tancredi and Klevén, 2011; Celada et al., 2013).

Table 1

| Serotonin receptor types, subtypes, locations and signaling mechanisms in the CNS |
|-----------------------------------------------|----------------|----------------|----------------|
| Receptor | Subtypes | Locations | Signaling mechanism | Cellular response | References |
| 5-HT1   | 1A, 1B, 1C 1D, 1E, 1F | raphe nuclei, hippocampus, cortex, striatum, amygdala, hypothalamus | Gq/11, AC, PKA, cAMP | Inhibitory | De Vivo and Maayani, 1986; Albert et al., 1992; Liu and Albert, 1991; Albert and Vahid-Ansari, 2019 |
| 5-HT2   | 2A, 2B, 2C | hippocampus, cortex, striatum, amygdala, hypothalamus | Gs; PLC, IP3 and DAG Na⁺, K⁺ ion channels | Excitatory | Roth et al., 1998; Xu and Pandey, 2000 |
| 5-HT3   | 3A, 3B | hippocampus, cortex, striatum, amygdala, basal ganglia | Gs; AC, PKA, cAMP | Excitatory | Pratt et al., 1990; Chameau and Voon Hooft, 2006 |
| 5-HT4   | | | | | |
| 5-HT5   | | | | | |
| 5-HT6   | | | | | |
| 5-HT7   | | | | | |

AC, adenylate cyclase; cAMP, cyclic Adenosine Monophosphate; DAG, Diacylglycerol; IP3, inositol trisphosphate; PKA protein kinase A; PLC, phospholipase C.
5-HT$_{1A}$ receptors can be classified into two distinct populations: presynaptic autoreceptors, located in the soma and dendrites of serotonergic neurons in the raphe nuclei, and postsynaptic heteroreceptors, which exist in dendrites and cell bodies of target non-5-HT neurons in 5-HT projecting areas (Fig. 1) (Verge et al., 1985; Riad et al., 2000; Palacios, 2016). At a presynaptic level, 5-HT$_{1A}$ receptor activation reduces the firing rate of raphe nuclei neurons, with a consequent decrease in the extracellular levels of 5-HT in its projection areas (Wang and Aghajanian, 1977; Verge et al., 1985; Sprouse and Aghajanian, 1986; Meller et al., 1990; Hjorth and Sharp, 1991). 5-HT$_{1A}$ heteroreceptors are located in non-serotonergic neurons, primarily in limbic areas such as the PFC, amygdala, septum, and hippocampus (Albert and Vahid-Ansari, 2019), where they can mediate neuroprotective effects (Fig. 1). In these areas, 5-HT$_{1A}$ receptors are expressed in the dendrites and soma of glutamatergic pyramidal neurons (Riad et al., 2000) and, axon terminals of GABAergic (Freund et al., 1990; Halasy et al., 1992) and cholinergic neurons (Cassel and Jeltsch, 1995). Typically, activation of heteroreceptors on distinct neurons reduces neuronal excitability and firing (Polter and Li, 2010). Finally, the presence of 5-HT$_{1A}$ receptors has been demonstrated in the cell body and processes of astrocytes (Whitaker-Azmitia et al., 1992). 5-HT$_{1A}$ expression in astrocytes was related to neuroprotective effects in Parkinsonian mice (Miyazaki et al., 2013; Miyazaki and Asanuma, 2016) and gerbils with cerebral ischemia (Lee et al., 2015) by promoting astrocyte proliferation and upregulation of antioxidative molecules.

Multiple 5-HT$_{1A}$ receptor signaling pathways have been identified in heterologous systems, but only a few of these pathways have been studied in neuronal systems. In general, the primary coupling linkage of the 5-HT$_{1A}$ receptor is linked via Gai/Gao to the inhibition of AC and a decrease in PKA activity (Fig. 2). 5-HT$_{1A}$ receptors also couple to ion channels, via G$_{i}$ subunits, activating inward rectifying potassium channel (GIRK) to hyperpolarize membrane potential and inhibit voltage-dependent Ca$^{2+}$ channels (VDCC) (Fig. 2) (Raymond et al., 1999; Albert and Vahid-Ansari, 2019). For other 5-HT$_{1A}$ receptor-G protein interactions, the G$_{i}/$γ complex is always released, which in turn can activate multiple effectors including the phosphorylated mitogen-activated protein kinase (MAPK), ERK1/2 and also PI3-kinase (PI3K)-Akt-GSK3β signaling pathways (Della Rocca et al., 1999). Differences in 5-HT$_{1A}$ autoreceptor and heteroreceptor coupling to G proteins are believed to underlie different signaling and desensitization (Haleem, 2019). The autoreceptors are reported to mainly couple with Gai while heteroreceptors are preferentially coupled to Goα in the hippocampus and with both Goα and Gai in the cortex (Mannoury la Cour et al., 2006). Therefore, the signaling pathway associated with the 5-HT$_{1A}$ receptor is probably determined by the precise signaling environment existing in a particular cell, even though the presence of other G proteins may redirect signal transduction to other existing pathways (Rojas and Fiedler, 2016).

A major pathway of the 5-HT$_{1A}$ receptor coupled to Gβ/γ complex is the ERK1/2, pathway mediated by phosphorylated MAPK/ERK kinase. Hydrolysis of MAPK precedes the stimulation of the critical enzymes ERK1/2, which activates the transcription factor of the cAMP-responsive binding protein (CREB). CREB has been shown to regulate neuronal proliferation and survival, neurogenesis, and dendritic remodeling (Carlezon Jr et al., 2005; Blendy, 2006). 5-HT$_{1A}$ receptor coupling to ERK1/2 is observed in the hippocampal-derived cell lines with endogenous expression of 5-HT$_{1A}$ receptors (Adayev et al., 1999) as well as in hippocampal tissue (Mehta et al., 2007a). The 5-HT$_{1A}$/CREB/ERK1/2 pathway seems to be important for neuronal protection (Albert and Vahid-Ansari, 2019). Direct stimulation of 5-HT$_{1A}$ receptor caused elevation in the expression of postsynaptic density protein (PSD)-95 and dendritic spine and synapse formation throughout sequential activation of MAPK isoenzymes ERK1/2 and protein kinase C alpha (PKCα) in both a mouse neuron-derived cell line (HN2-5) and in organotypic hippocampal slice cultures from postnatal day 15 (P15) mice (Debata et al., 2010). The same pathway PKCα/ERK1/2 augmented PSD-95 and synaptogenesis in the hippocampus of in vivo mice (Mogha et al., 2012). These findings indicated that PKCα constitutes a direct substrate of ERK1/2 in neuronal cells and might have a role in the neuroprotection of hippocampal neurons (Mogha et al., 2012). However, the effects of 5-
HT$_{1A}$ receptor activation of ERK on neurons vary and appear to depend on their location in different brain regions. For example, 5-HT$_{1A}$ receptor activation inhibits ERK1/2 phosphorylation in RN46A cells, a model of serotonergic raphe nucleus neurons that express endogenous 5-HT$_{1A}$ receptors (Kushwaha and Albert, 2005). Besides, endogenous 5-HT$_{1A}$ receptors did not couple to activation of ERK1/2 in primary cultures of rat hippocampal neurons (Cowen et al., 2005).

The PI3K/Akt pathway has been found to confer neuroprotection by inhibiting apoptosis in several experimental conditions (Tamatani et al., 1998; Matsuzaki et al., 1999; Yamaguchi et al., 2001). Activation of PI3K/Akt pathway by 5-HT$_{1A}$ receptor resulted in translocation of the nuclear transcription factor-kB (NF-kB) which was required for inhibiting caspase 3 activation in transfected Chinese hamster ovary cells (Hsiung et al., 2005). The PI3-K/Akt pathway has been implicated in the regulation of cell growth, survival, and proliferation as well as in synaptic plasticity (Kim et al., 2004). However, the exact mechanism of how 5-HT$_{1A}$ receptors couple to the PI3K pathway in neurons is still unclear (Albert and Vahid-Ansari, 2019).

The signaling pathways associated with 5-HT$_{1A}$ receptors are probably determined by the precise $G_{q/11}$ isoform existing in cells and cascades involving $G_{b/\gamma}$ signaling. 5-HT$_{1A}$ receptor activation may impact neuronal plasticity and decrease neurodegeneration likely by modulation of MAPK/ERK and PI3K/Akt signaling pathways (Chilmonczyk et al., 2015; Rojas and Fiedler, 2016; Albert and Vahid-Ansari, 2019; Sharp and Barnes, 2020). Of note, those signaling pathways have been suggested to be involved in neuroprotective mechanisms including the stimulation of nuclear factor-kB (NF-kB), inhibition of caspase 3, and increasing the expression of the antiapoptotic protein Bcl-2 (Chilmonczyk et al., 2015).

4. 5-HT$_{1A}$ receptors as a potential target for neuroprotection in cerebral ischemia

4.1. Cerebral ischemia

Cerebral ischemia is one of the principal causes of death and disability worldwide and represents an increased economic burden due to treatment and post-ischemia care (Chamorro et al., 2016; Benjamin et al., 2018; Rajsic et al., 2019; Johnson et al., 2019). Cerebral ischemia occurs as a result of the transient or permanent reduction in the cerebral blood flow (CBF) in restricted brain regions (focal cerebral ischemia or stroke) or the whole brain (global cerebral ischemia). Focal cerebral ischemia (FCI) has been categorized as either ischemic or hemorrhagic. Ischemic stroke is caused by the interruption of CBF to the brain due to a

![Fig. 2. Signaling transduction pathways linked to 5-HT$_{1A}$ autoreceptors and/or postsynaptic heteroreceptors.](image-url)
thrombotic or embolic occlusion in a particular cerebral artery. Hemorrhagic strokes occur within the brain ruptures. Globally, ischemic stroke accounts for 87% of stroke cases and it is the third most frequent cause of death for people over 60 years old in developed countries. Hemorrhagic stroke accounts for the remaining 13% of patients (Chamorro et al., 2016; Johnson et al., 2019). According to a report from the Johnson et al. (2019) Lifetime Risk of Stroke Collaborators, the global lifetime risk of stroke from the age of 25 years onward was approximately 25% among both men and women (Johnson et al., 2019; GBD, 2016).

Prolonged circulatory deficits may induce dramatic neuronal damage, leading to a broad range of neuropsychological and behavioral dysfunctions, such as motor impairments, cognitive deficits, and emotional symptoms (Anderson and Arciniegas, 2010). Motor deficits are the most common symptom after stroke and are present in up to 77% of the patients (Lawrence et al., 2001). Studies on cognitive impairment after cerebral ischemia have reported rates ranging from 35% to 87% (Hoffmann et al., 2011; van Rosij et al., 2014; Delavaran et al., 2017). Anxiety and post-stroke depression range from 29% to 52% (Ayerbe et al., 2013; Hackett and Pickles, 2014; Knapp et al., 2017). The neuropsychiatric sequelae of cerebral ischemia are disabling and can have a negative influence on recovery, reduce the quality of life, and lead to exhaustion of the caregivers.

In general, stroke is characterized by an infarcted core, where cell death occurs within minutes after arterial occlusion and the peri-infarcted region surrounding the infarction named penumbra where there is a partial reduction in blood supply; this region represents an area to which therapeutic neuroprotective interventions can be directed (Povroznik et al., 2018). The nature and severity of FCI consequences depend mainly on the location and extent of the injury.

Experimentally, FCI can be modeled through transient or permanent occlusion of the middle cerebral artery (MCA) in mice or rats. MCA occlusion (MCAo) models have been used extensively because they reproduce the pattern of ischemic cerebral damage and the functional disabilities such as neurological deficits, including sensorimotor changes which are also often observed in human stroke patients (Traystman, 2003; Hermann et al., 2019). In general, MCAo results in a significant reduction of CBF in both striatum and cortex. However, the degree and distribution of blood flow reduction depend on the duration of MCAo, the site of occlusion along with the MCA, and the amount of collateral blood flow into the MCA territory (Traystman, 2003; Gennaro et al., 2019). These factors determine the size of the lesion. Considerable variability in the extension of infarct size and behavioral outcomes have been recurrent findings with this model and compromised in part its potential in preclinical studies (Bardutzky et al., 2005; Senda et al., 2011).

Transient global cerebral ischemia (TGCI) results from unexpected reversible cardiac arrest, severe respiratory arrest, gas poisoning, perinatal asphyxia, and diagnostic and surgical procedures. Patients that survive TGCI may experience a wide range of long-term dysfunctions, the most prominent of which are cognitive deficits, attention deficits, verbal communication deficiency, spatial/temporal disorientation, impaired decision-making, anxiety, and depression (Anderson and Arciniegas, 2010). TGCI can be modeled through bilateral typical carotid artery occlusion (BCCAO) in mice and Mongolian gerbils and via two vessels (2-VO) or four- vessel occlusion (4-VO) in rats (León-Moreno et al., 2020). Usually, TGCI affects areas of the forebrain, such as the highest vulnerable hippocampal pyramidal neurons (CA1 and CA3 regions), the middle-sized dorsoventral striatum neurons, and the pyramidal neurons in the PFC (Raval et al., 2009; Li et al., 2011; Khodanovich and Kiesel, 2015). This leads to the loss or severe impairment of brain functions that include motor coordination, grip strength, and cognitive and memory abilities. As for MCAo models, the degree of damage to the brain areas will decide the fate of brain functioning (Knowles et al., 2016).

4.2. Pathophysiology of cerebral ischemia

The pathophysiological mechanisms that eventually lead to the degeneration of cerebral tissue due to FCI or TGCI seem to be similar (Dirmagl et al., 1999; Leker and Shohami, 2002; Mehta et al., 2007b; Chamorro et al., 2016; Anrather and Iademela, 2016). They comprise a multitude of pathways, often interconnected and overlapped, that 17) operate at different time points and locations in the extra- and intra- cellular milieu. The chain of processes begins with the breakdown of ion homeostasis in the neuronal membrane, particularly the failure of the Na⁺/K⁺-adenosine triphosphate pump caused by the energetic collapse. Anoxic depolarization, together with the massive release of glutamate by presynaptic terminals, then occurs. Glutamate stimulates N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. It promotes the continuous influx of Ca²⁺, which in turn activates a series of enzymes and increases oxidative stress in the adjacent postsynaptic cells. These changes occur within minutes and comprise the excitotoxic phase of brain ischemia, with necrotic cell death in the infarcted core. An endogenous protective mechanism against the excess of membrane depolarization that is initiated by reduced energy stores is mediated by the ATP-sensitive K⁺ channel. Usually closed in normal conditions, this channel is activated rapidly under cerebral ischemic conditions, causing K⁺ efflux, limiting neuronal excitability and Ca²⁺ influx, and thus blocking the subsequent neurotoxic biochemical cascade (Liao et al., 2010). Oxidative and nitrosative stress are partly consequences of excitotoxicity and result from an increase in secondary messenger systems coupled to the enzymatic generation of reactive oxygen species (ROS) including superoxide anions, hydrogen peroxide, hydroxyl radicals, and peroxynitrite (Fukuyama et al., 1998). ROS and reactive nitrogen species are shown to act directly as executioners of neuronal cell death during cerebral ischemia (Chan, 2001).

Robust sterile neuroinflammation starts a few hours after the onset of cerebral ischemia and is characterized by blood-brain barrier (BBB) disruption, infiltration of peripheral leukocytes, activation of microglia and astrocytes, and the release of molecules known as damage-associated molecular patterns (DAMPs) by injured and dying cells (Liesz and Kleinschntzt, 2016). Activated immune cells triggered by DAMPs produce inflammatory cytokines, chemokines, and other cytotoxic mediators, leading to exacerbation of cerebral ischemic injury (Gelderblom et al., 2009; Chen and Nuñez, 2010; Yamaguchi et al., 2020). The first immune cell to respond to ischemic injury is brain-intrinsic microglia, followed by astrocytes and neutrophils that exacerbate oxidative stress and BBB damage (Justicia et al., 2003). Monocytes, monocyte-derived macrophages, dendritic cells, natural killer cells, and lymphocytes regulate post-ischemic inflammation and may have beneficial or detrimental roles on cerebral injury (Liesz and Kleinschntzt, 2015).

Concomitantly to all neurodegenerative processes, at a particular time point after cerebral ischemia, protective and repair mechanisms such as an increase in the expression of anti-inflammatory mediators and neurotrophic factors and, reactive angiogenesis and neurogenesis take place (Ding et al., 2008; Dirmagl, 2012; Rajkovic et al., 2018). In particular, the cAMP/PKA/pCREB pathway which is closely linked to synaptic plasticity, neurogenesis, and axon growth has been considered a fundamental process that is involved in the recovery of neural function following cerebral ischemic injury (Kitagawa, 2007; Sasaki et al., 2007; Zhang et al., 2007; van Os et al., 2015). In recent years, scientists have demonstrated that the cAMP/PKA/CREB signaling pathway and the downstream CREB effector brain-derived neurotrophic factor (BDNF) can exert neuroprotective effects in ischemic brain injury. CREB expression is upregulated in the brain after MCAo (Salminen et al., 1995), transient global cerebral ischemia (Soares et al., 2016; Mori et al., 2017), and hypoxia-ischemic (HI) injury (Zaitseva et al., 2005; Carloni et al., 2010). Intra-ventricular administration of BDNF attenuated hippocampal damage after global forebrain ischemia (Beck et al., 1994; Wu and Pardridge,
Moreover, reperfusion itself is associated with further neuronal damage by activation neuroinflammatory response, thus causing tissue injury (Ohir et al., 2020). Antiplatelet drugs, anticoagulants, and statins act as prophylactics and have no immediate effect following an acute ischemic attack (Tajiri et al., 2013). Therefore, there is a substantial need for neuroprotective strategies to prevent neuronal damage and promote functional recovery after cerebral ischemia.

6. Experimental evidence and putative mechanisms underlying the neuroprotective effects of 5-HT\textsubscript{1A} receptor agonists in experimental cerebral ischemia

6.1. 5-HT\textsubscript{1A} agonists and MCAo models

Studies on the involvement of the 5-HT\textsubscript{1A} receptor in cerebral ischemia advanced from the 1990s onwards after the development of selective 5-HT\textsubscript{1A} receptor agonists. Bielenberg and Burkhardt (1990) have shown the effects of acute treatment with various 5-HT\textsubscript{1A} receptor agonists, including the full agonists 8-OH-DPAT and BayR 1531, or partial agonists as buspirone, gepirone, and ipsapirone, in mice and rats subjected to permanent MCAo (Table 2). In general, the drugs administered 30 min before or 60 min after MCAo and caused a significant reduction in the infarct volume in the cerebral cortex. Ipsapirone and Bay R 1531 reduced cortical infarct size by more than 60% as compared to controls.

Neuroprotective effects have also been shown with partial agonists including CM 57943, urapidil, SI467,1 and ipsapirone in rodents subjected to MCAo (Prehn et al., 1991, 1993; Kamei et al., 2001; Johansen et al., 2014). Both 5-HT\textsubscript{1A} agonists CM 57943 and urapidil promoted a decrease in the size of infarct in the cerebral cortex of ischemic rodents (Table 2). Moreover, these 5-HT\textsubscript{1A} agonists were able to reduce neuronal damage of cultured neocortical and hippocampal neurons subjected to chemical hypoxia or glutamate overload in a dose-dependent manner (Prehn et al., 1993). Similarly, the potent 5-HT\textsubscript{1A} agonist, compound 26 (2-(6-[(3,4-dihydro-2-chorometh-2-ylmethyl)amino]hexyl)tetrahydro-1H-pyrrolo[1,2c] imidazole-1,3(2H)-dione), has produced neuroprotective effects in both in vitro assays using primary cell cultures from rat hippocampus as well as in rats with MCAo (Table 1) (Marco et al., 2011). Repinotan was also effective in decreasing the infarct size when administered 4 h after MCAo (Semkova et al., 1998; Mauler and Horváth, 2005).

In another study, Kamei et al. (2001) have demonstrated the neuroprotective effects of buspirone and compound 5 (SUN N 4057) in rats subjected to MCAo. In this study, the measurement of peripheral type benzodiazepine binding sites (PTBBS) in ipsilateral cortical and striatal homogenates was carried out as an index for quantification of neuronal damage 10 days after cerebral ischemia. A single administration of compound 5 exerted a dose-dependent reduction of PTBBS levels and reduced the ischemic hyperthermia at neuroprotective doses.

Extensive preclinical studies have been done with the full 5-HT\textsubscript{1A} receptor agonist, repinotan (Bay X 3702) after permanent (Semkova et al., 1998) or transient (Mauler and Horváth, 2005; Kukley et al., 2001) MCAo. Repinotan, when administered immediately after reperfusion or even 5 h later, reduced the cortical infarction volume up to 97% in rats with MCAo. In vivo, the activity of repinotan was abolished by WAY 100635, indicating that the effect was mediated via 5-HT\textsubscript{1A} receptor stimulation. Also, repinotan elevated the level of the apoptosis-inhibiting protein BCL-2 in the ipsilateral cerebral cortex of ischemic animals, indicating a neuroprotective effect of repinotan treatment (Kukley et al., 2001).

The favorable neuroprotective efficacy, broad dose-response curve, and prolonged therapeutic window observed in those stroke models positioned repinotan as a promising candidate for clinical trials for treating acute ischemic stroke in humans (Berends et al., 2005). The tolerability, safety, and dose of repinotan were investigated in Phase II double-blind, placebo-controlled study in which 240 patients with acute hemispheric ischemia (focal ischemia) received placebo or repinotan at 0.5, 1.25 or 2.5 mg/kg given i.v. infusion during 72 h. Treatment was started within 6 h of symptoms onset and evaluations were performed at one and 3 months later. Although both doses of 0.5 mg/kg/day and 1.25 mg/kg/day were well tolerated with few patients requiring discontinuation, a higher incidence of serotonergic side effects including shivering, heavy sweating, restlessness, agitation and confusion was detected in the 2.5 mg/kg/day dosage group (Teal et al., 2005). To optimize repinotan exposure of patients with stroke, a Randomized Exposure Controlled Trial (RECT) was designed for a Phase IIB study with repinotan (Teal et al., 2009). Several changes were implemented after the randomization of 98 patients into RECT and included: i) reduction of the allowed treatment time window from 6 to 4.5 h to increase the potential for neuroprotective effect; ii) a loading dose to reach target plasma concentrations sooner; and iii) patient assignment in a 1:1 ratio to treatment with repinotan or placebo (changed from 2:1 in RECT). However, this study failed to demonstrate a clinical benefit of repinotan and the development of repinotan in ischemic stroke was discontinued (Teal et al., 2009).

Finally, other preclinical results have supported the direct involvement of 5-HT\textsubscript{1A} receptors in neuroprotective therapies for cerebral ischemia. In this respect, cannabidiol, which is the second most abundant Cannabis sativa derived cannabinoid, reduced the infarct volume and increased the CBF in mice with MCAo. The effect of cannabidiol was inhibited by the 5-HT\textsubscript{1A} antagonist, WAY100635, but not by a CB1 receptor antagonist or by a vanilloid receptor antagonist (Mishima et al., 2005).

6.2. 5-HT\textsubscript{1A} receptor agonists and TGCI models

Transient global cerebral ischemia is characterized by an abrupt and complete reduction of blood flow and glucose, which causes selective neuronal injury to vulnerable brain areas such as the hipocampus. As shown in Table 2, single administration of CM 57943, urapidil, repinotan, ipsapirone and repinotan (BAY R 1531), 15 to 30 min before or immediately after 2-VO resulted in a reduction of neuronal loss in the CA1 hippocampal subarea and entorhinal cortex of rats (Prehn et al., 1991, 1993; Schaper et al., 2000). The anti-apoptotic effect of repinotan was abolished by cotreatment with the 5-HT\textsubscript{1A} receptor antagonist WAY100635 (Schaper et al., 2000). A 7-day infusion with the 5-HT\textsubscript{1A} agonist, 8-OH-DPAT, prevented the neuronal loss in the hippocampal CA1 subarea induced by 2-VO in rats. Hypothermia was proposed as a possible explanation for the neuroprotective effect of 8-OH-DPAT (Torup et al., 2000).

Mongolian gerbils have unique vascular anatomy with no posterior
Table 2

5-HT<sub>1A</sub> receptor agonists and animal models of cerebral ischemia

<table>
<thead>
<tr>
<th>Animal model/ specie</th>
<th>Treatment</th>
<th>Administration</th>
<th>Histopathology/ Functional parameters</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCAo/ rats and mice</td>
<td>8-OH-DPAT (1 mg/kg, s. c.)</td>
<td>30 min before ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Bielenberg and Burkhardt, 1990</td>
</tr>
<tr>
<td></td>
<td>Buspirone (10 mg/kg, i. p.)</td>
<td>1 h after ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>gepirone (10 mg/kg, i.p.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L-6206 (10 and 30 mg/kg, i.p.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bay R 1531 (1 mg/kg, i. p.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L-6206 (1 mg/kg, i. p.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCAo/ rats and mice</td>
<td>CM 57943 (1, 5, 10 mg/kg, i.p.)</td>
<td>30 min before ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Prehn et al., 1991</td>
</tr>
<tr>
<td></td>
<td>CM 57943 (1, 5, 10 mg/kg, i.p.)</td>
<td>Immediately and 60 min after ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCAo/ rats</td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>30 min before ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Prehn et al., 1993</td>
</tr>
<tr>
<td></td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>CM 57943 (10 mg/kg, i. p.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Repinotan (12 and 40 μg/kg/h, i.v.)</td>
<td>4 h immediately after ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Semkova et al., 1998</td>
</tr>
<tr>
<td></td>
<td>Repinotan (1, 2 μg/kg, i.v)</td>
<td>Immediately after ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Kukley et al., 2001</td>
</tr>
<tr>
<td>MCAo/ rats</td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>30 min before ischemia</td>
<td>↑ BCL-2 in ipsilateral cortex</td>
<td>Kamei et al., 2001</td>
</tr>
<tr>
<td></td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>CM 57943 (10 mg/kg, i. p.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Piclozotan (0.1, 0.3, 1 mg/kg, s.c.)</td>
<td>Immediately after ischemia</td>
<td>↓ PTBBS in cortical and striatal homogenates</td>
<td>Mauler and Horvath, 2005</td>
</tr>
<tr>
<td></td>
<td>Repinotan (1, 0.75 mg/kg, i.v)</td>
<td>0, 2 and 4 h after ischemia</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Johansen et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Repinotan (3 μg/kg, i.v)</td>
<td>Immediately, 5 h after occlusion and continuing during 4 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Repinotan (3 and 10 μg/kg/h, i.v)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCAo/ mice</td>
<td>Cannabidiol (1 and 3 mg/kg, i.p.)</td>
<td>Immediately before and 3 hours after MCA occlusion</td>
<td>↓ infarct volume in the cerebral cortex</td>
<td>Mishima et al., 2005</td>
</tr>
<tr>
<td></td>
<td>Ipsapirone (0.75 mg/kg, i. v)</td>
<td></td>
<td>↑ cerebral blood flow</td>
<td></td>
</tr>
<tr>
<td>MCAo/ rats</td>
<td>Compound 26 (40 μg/kg/h, i.v.)</td>
<td>Infusion during 4 h immediately after ischemia</td>
<td>*Effects blocked by WAY100635</td>
<td>Marco et al., 2011</td>
</tr>
<tr>
<td></td>
<td>Si4671 (0.06 mg/kg/h, i.v.)</td>
<td>30 min after reperfusion and continuing 20 h</td>
<td>↓ size and infarct volume in the cerebral cortex</td>
<td>Johansen et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Si4671 (0.75mg/kg, s.c.)</td>
<td>30 min after reperfusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ipsapirone (0.25 mg/kg/h, i.v.)</td>
<td>30 min after reperfusion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TGCI Animal model/ specie</th>
<th>Treatment</th>
<th>Administration</th>
<th>Histopathology / Functional parameters</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-VO/ rats</td>
<td>CM 57943 (1, 5, 10 mg/kg, i.p.)</td>
<td>30 min before ischemia</td>
<td>↓ neuronal loss in the CA1 hippocampal subarea (CM 57943)</td>
<td>Prehn et al., 1991</td>
</tr>
<tr>
<td></td>
<td>CM 57943 (1, 5, 10 mg/kg, i.p.)</td>
<td>Immediately and 60 min after ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-VO/ rats</td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>30 min before ischemia</td>
<td>↓ neuronal loss in the CA1, CA2, CA3 hippocampal subareas and entorhinal cortex</td>
<td>Prehn et al., 1993</td>
</tr>
<tr>
<td></td>
<td>Ipsapirone (10 mg/kg, i.p.)</td>
<td>CM 57943 (10 mg/kg, i. p.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urapidil (80 mg/kg, i.p.)</td>
<td>CM 57943 (10 mg/kg, i. p.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Repinotan (4 μg/kg, i.v.)</td>
<td>Infusion during 4 h immediately after ischemia</td>
<td>↓ neuronal loss in the CA1 hippocampal subarea</td>
<td>Schaper et al., 2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ apoptosis (TUNEL)</td>
<td></td>
</tr>
</tbody>
</table>
and treated with 5-HT receptor protective effects have been detected in gerbils subjected to BCCAO signs and death of hippocampal CA1 neurons (Traystman, 2003). Communicating artery, which connects the carotid and vertebrobasilar arterial system. Thus, BCCAO in gerbils results in severe neurological signs and death of hippocampal CA1 neurons (Traystman, 2003). Neurprotective effects have been detected in gerbils subjected to BCCAO and treated with 5-HT1A receptor agonists (Table 2). Ispapirone, and Bay R 1531 attenuated neuronal loss in the hippocampal CA1 region in gerbils subjected to BCCAO (Bode-Greuel et al., 1990; Salazar-Colocho et al., 2007, 2008). Bay R1531 showed a powerful neurprotective effect with 100% preservation of neurons while gepirone and 8-OH-DPAT were ineffective. Besides, Piera et al. (1995) have observed that 8-OH-DPAT, buspirone, and flesusinoxan abolished the hyperactivity induced by BCCAO in gerbils. However, the authors found no correlation between the behavioral effects of those 5-HT1A agonists and the extent of their reduction in neuronal damage: only 8-OH-DPAT reduced neuronal degeneration induced by cerebral ischemia. It was suggested that the ineffectiveness of buspirone and flesusinoxan may have been related to the partial agonist activity of those compounds at the 5-HT1A receptor.

Salazar-Colocho et al. (2007, 2008) demonstrated that pretreatment with 8-OH-DPAT increased BDNF levels and prevented the neuronal loss in the hippocampal CA1 region of gerbils with BCCAO. Also, pretreatment with 8-OH-DPAT decreased phosphorylation of NMDA receptors in the hippocampus of ischemic gerbils, attenuating neurotoxicity and neuronal loss (Tingley et al., 1997). The authors concluded that NR1 phosphorylation and BDNF accounted, at least in part, for the neuroprotective effects of pretreatment with 8-OH-DPAT.

### 7. New perspectives for targeting 5-HT1A receptors: ‘biased’ receptor agonists differentiating between receptor subpopulations

The studies described above and listed in Table 2 provide a clear demonstration that parameters associated with cerebral ischemia, can be reduced via activation of 5-HT1A receptors. Overall, 5-HT1A receptor agonists reduced the size and infarct volume in the cerebral cortex of rodents subjected to MCAo and prevented hippocampal neuronal loss in the hippocampus of rodents with global cerebral ischemia. Such studies butress the rationale for pursuing investigation of this class of compounds and suggest that they could lead to promising pharmacotherapeutics. Nevertheless, the clinical benefits for ischemia patients are currently far from impressive. The only commercialized drug in Table 2 is buspirone, which is commonly used as an anxiolytic though it has attracted little (if any) attention as a clinical anti-ischemia treatment. Interestingly it has been used as an anti-shivering treatment during the intervention by cooling body temperature because if left uncontrolled, shivering can defeat the cooling process and eliminate the potential intervention by cooling body temperature because if left uncontrolled, shivering can defeat the cooling process and eliminate the potential benefits of therapeutic intervention in brain ischemia, see EuroHYP-1 and ICTUS2/3 trials on clinicaltrials.gov. Some of the other compounds, including isapipirone and gepirone, are close clinical analogs of buspirone and possess similar pharmacological profiles, i.e., partial agonist properties at 5-HT1A receptors and some limited selectivity over multiple other cross-reacting sites, including dopaminergic and adrenergic receptors. Similar limitations also apply to urapidil and piclozox although not to repinotan, which is potent and selective for 5-HT1A receptors. As surmised by Piera et al. (1995), the limited neuroprotective effects of at least some of the tested compounds may also be actually due to their insufficient agonist efficacy at 5-HT1A receptors. Thus, modest-efficacy partial receptor agonism may be insufficient to elicit an optimal therapeutic benefit.

Another important point to consider is that the tested compounds interact broadly with 5-HT1A receptor subpopulations throughout the brain, irrespective of neuronal or regional localization. This lack in receptor discrimination may be a limiting factor in the anti-ischemic efficacy of the agonists because 5-HT1A receptors in different brain regions can mediate diverging or even contradictory responses. For example, activation of 5-HT1A autoreceptors in the raphe inhibits serotonergic tone and dampens 5-HT release throughout terminal regions, thus indirectly opposing activation of postsynaptic 5-HT1A receptors (Fig. 2). Moreover, as described above, the preferential targeting by biased agonists of raphe-located 5-HT1A autoreceptors or post-synaptic hetero-receptors is not due to differences in the receptor protein itself or binding affinity per se. The distinct responses to the biased 5-HT1A agonists have been attributable to regional coupling differences of the 5-
HT1A receptors to certain G-protein subtypes, regulators of G-protein signaling, or transcriptional regulation (Newman-Tancredi, 2011). There are distinct regional intracellular signaling responses to postsynaptic 5-HT1A receptor activation: ERK1/2 signaling, which is important for neuroprotective activity, varies in different brain regions (vide supra) and is known to be stimulated by 5-HT1A receptors in the cortex and hippocampus. Taken together, these considerations suggest that improved treatment of ischemia may require 5-HT1A receptor agonists that fulfill 3 conditions: (i) high receptor selectivity, (ii) efficacious receptor activation (full agonism), and (iii) functional selectivity for ERK1/2 activation in vulnerable brain regions expressing postsynaptic 5-HT1A heteroreceptors. These criteria have not previously been met by classical 5-HT1A receptor agonists but a new generation of compounds has become available that discriminate between receptor subpopulations in specific brain regions (Sniecikowska et al., 2019). An extensive series of in vitro, ex vivo, electrophysiological, neurochemical, behavioral, and brain imaging studies have shown that these ‘biased agonists’ differentially target 5-HT1A autoreceptors or postsynaptic 5-HT1A heteroreceptors in different brain regions (Newman-Tancredi, 2011). The prototypical postsynaptic 5-HT1A receptor biased agonist is NLX-101 (also known as F15599), a compound that preferentially and potently activates ERK1/2 phosphorylation and elicits cortical pyramidal neuron electrical activity without inhibiting serotonin neuron firing (Newman-Tancredi et al., 2009; Lladé-Pelfort et al., 2010). NLX-101 is undergoing early clinical development for breathing difficulties in Rett’s syndrome and as a potential rapid-acting antidepressant. Indeed, NLX-101 exhibits pro-cognitive and antidepressant activity in a variety of animal models (Depoortere et al., 2016; van Goethem et al., 2015; Depoortere et al., 2019). Notably, a recent study by Aguiar et al. (2020) showed that chronic treatment with NLX-101 attenuated cognitive impairments and despair-like behaviors induced by BCCAO in mice. Also, NLX-101 blocked the increase in plasma corticosterone levels and restored BDNF, synaptophysin, and PSD-95 protein levels in the hippocampus of mice subjected to BCCAO. These findings are significant because they suggest that preferential targeting of postsynaptic 5-HT1A receptors may be able to rescue the neurostructural damage induced by BCCAO as well as its functional deficits on mood and cognitive function. If these findings can be translated into a clinical setting, they could provide a novel basis for the development of ‘biased’ 5-HT1A heteroreceptor agonists in the treatment of ischemia.

8. General considerations and conclusions

The primary purpose of neuroprotective pharmacotherapy is to reduce the severity of initial damage and improve functional outcomes in the weeks and months after a cerebral ischemic event. In this review, we presented experimental evidence that 5-HT1A receptor agonists were able to prevent the neuronal damage induced by transient focal or global cerebral ischemia. Indeed, over several decades abundant evidence has been provided that 5-HT1A receptors are involved in several processes that may attenuate cerebral ischemic injury at varying time points. Agonist activation of 5-HT1A receptors can promote hyperpolarization due to an increase in the inwardly rectifying potassium current and inhibit ischemia-induced excessive damage due to glutamate release. Besides, 5-HT1A receptor agonists have been reported to exert neuroprotective effects by promoting hypothermia. Finally, 5-HT1A receptor agonists have been involved in the neuroplastic changes in the hippocampus, including an increase in BDNF and neurogenesis which are reduced after a cerebral ischemic event.

Nevertheless, despite these compelling findings, little progress has been made in translating them into a clinical application. Most of the preclinical studies have focused on acute or short-term treatments, i.e., before, immediately after, or during 3 to 7 days after cerebral ischemia (Table 2), to promote neuronal survival. The main measurement (outcome) was the histological damage in vulnerable areas (cortical infarct size for MCAo and hippocampal cell loss for TGCI). However, the promotion of neuronal survival is of little therapeutic utility unless followed by successful brain remodeling and plasticity - which is which 5-HT1A receptor agonists produce neuroprotection need more clarification and systematic studies. Only two studies confirmed direct 5-HT1A receptor involvement by showing that the neuroprotective effect of 5-HT1A receptor agonists was blocked by a 5-HT1A receptor antagonist, WAY100635 (Schaper et al., 2000; Mishima et al., 2005). Restoring functional deficits in ischemic patients is critical for improvements in the patient’s quality of life and is, therefore, an important measure of a treatment’s therapeutic potential in animal models (Liao et al., 2008; Veerbeek et al., 2011). To our knowledge, only two studies measured functional recovery with a 5-HT1A receptor agonist after cerebral ischemia (Piera et al., 1995; Aguiar et al., 2020). Interestingly, one of those studies indicates that the postsynaptic 5-HT1A heteroreceptor is involved in both neuroprotection and functional recovery, drawing attention to a possible novel and promising strategy for improved therapeutic intervention. A bias for postsynaptic receptors is important as excessive and indistinct activation of both pre- and postsynaptic 5-HT1A receptors may induce a broad range of physiological effects related to the expression of these receptors in different brain regions. Hence, as well as the desired neuroprotective properties, 5-HT1A receptor activation can elicit autonomic, neuroendocrine, neuropsychiatric, and hypothermic effects, depending on the brain regions involved. In this context, it is important to note that the classical 5-HT1A receptor agonists activate indiscriminately both 5-HT1A autoreceptors, which induce an inhibitory effect on serotonergic tone, and postsynaptic heteroreceptors, which are associated with inducing a positive effect on neuroprotective mechanisms. Such lack of functional selectivity may result in a limited net beneficial effect of such agonists, possibly dampening therapeutic efficacy and thus reducing their clinical applications. The development of a biased 5-HT1A receptor agonist targeting postsynaptic heteroreceptors might overcome such limitations and represent an attractive therapeutic strategy to provide neuroprotection in ischemic cerebral conditions.

Declaration of Competing Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AN-T is employee and/or stockholder of Neurolixis, Inc. RPA, JP and RMWO declare that there is no conflict of interest.

Acknowledgements

The authors gratefully acknowledge the financial support by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Program CAPES/NUIFIC 8888.7156.527/2017-00), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), State University of Maringá and the University of Maastricht.

References


